Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Biagio Ricciuti

Showing results (1-10 of 207) with videos related to

Pageof 21
Sort By:
Journal of Thoracic Disease|April 19, 2019
Osimertinib for <i>EGFR</i>-mutant non-small cell lung cancer: place in therapy and future perspectivesBiagio Ricciuti
Translational Lung Cancer Research|May 22, 2018
First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLCBiagio Ricciuti, Rita Chiari
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 7, 2024
Precision Immunotherapy for STK11/KEAP1-Mutant NSCLCBiagio Ricciuti, Marina Chiara Garassino
JAMA Oncology|December 15, 2022
Atezolizumab Plus Bevacizumab in TMB-High Non-Small Cell Lung Cancers-The Hunt for Predictive Biomarkers to Optimize Treatment SelectionBiagio Ricciuti, Mark M Awad
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2022
Reply to Kus and AktasBiagio Ricciuti, Mark M Awad
Cancer Journal (Sudbury, Mass.)|December 10, 2020
What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?Biagio Ricciuti, Mark M Awad
JTO Clinical and Research Reports|September 30, 2021
Reply to Cortellini ABiagio Ricciuti, Mark M Awad
BMJ Case Reports|December 16, 2015
Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinkingBiagio Ricciuti, Alberto Rebonato, Enrico Capodicasa
Journal of Thoracic Disease|October 22, 2019
Impact of performance status and age on osimertinib efficacy in patients with <i>EGFR</i>-mutant T790M-positive non-small-cell lung cancerGiuseppe Lamberti, Elisa Andrini, Biagio Ricciuti
JAMA Oncology|September 18, 2025
Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer-ReplyEdoardo Garbo, Biagio Ricciuti, Federico Cappuzzo
Pageof 21

Showing results (1-10 of 207) with videos related to

Sort By:
Pageof 21
Journal of Thoracic Disease|April 19, 2019
Osimertinib for <i>EGFR</i>-mutant non-small cell lung cancer: place in therapy and future perspectivesBiagio Ricciuti
Translational Lung Cancer Research|May 22, 2018
First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLCBiagio Ricciuti, Rita Chiari
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 7, 2024
Precision Immunotherapy for STK11/KEAP1-Mutant NSCLCBiagio Ricciuti, Marina Chiara Garassino
JAMA Oncology|December 15, 2022
Atezolizumab Plus Bevacizumab in TMB-High Non-Small Cell Lung Cancers-The Hunt for Predictive Biomarkers to Optimize Treatment SelectionBiagio Ricciuti, Mark M Awad
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2022
Reply to Kus and AktasBiagio Ricciuti, Mark M Awad
Cancer Journal (Sudbury, Mass.)|December 10, 2020
What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?Biagio Ricciuti, Mark M Awad
JTO Clinical and Research Reports|September 30, 2021
Reply to Cortellini ABiagio Ricciuti, Mark M Awad
BMJ Case Reports|December 16, 2015
Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinkingBiagio Ricciuti, Alberto Rebonato, Enrico Capodicasa
Journal of Thoracic Disease|October 22, 2019
Impact of performance status and age on osimertinib efficacy in patients with <i>EGFR</i>-mutant T790M-positive non-small-cell lung cancerGiuseppe Lamberti, Elisa Andrini, Biagio Ricciuti
JAMA Oncology|September 18, 2025
Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer-ReplyEdoardo Garbo, Biagio Ricciuti, Federico Cappuzzo
Pageof 21